Clinic
Guardian Health Clinic, LLC
Guardian Health Clinic, LLC was paid $2.20M by Medicaid between Jan 2018 and Nov 2024, across 63 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 52% of everything it billed.
33Billing provider infoGUARDIAN HEALTH CLINIC, LLC
RAYVILLE, LA 71269
RAYVILLE, LA 71269
33aNPI1437681178assigned 03/31/2017
33bProvider typePrimary Care Clinic/Center
28Total paid$2.20M
24GClaims137,107
24DCodes billed63
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Primary Care Clinic/Center providers in Louisiana
Rank by total paid#11 of 92
Median peer was paid$157K
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,481 | $88K | |
| 2019 | 6,393 | $111K | |
| 2020 | 11,754 | $236K | |
| 2021 | 23,653 | $434K | |
| 2022 | 32,127 | $538K | |
| 2023 | 37,817 | $539K | |
| 2024incomplete | 20,882 | $256K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 52% | 27,095 | 16,613 | $1.15M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 10% | 7,624 | 5,773 | $223K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 8.6% | 3,668 | 2,561 | $190K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 7.0% | 6,131 | 4,342 | $155K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 5.1% | 1,560 | 1,323 | $113K |
| 87634 | 2.8% | 1,517 | 1,075 | $63K | |
| 71046 | Radiologic examination, chest; 2 views | 1.8% | 2,977 | 2,362 | $40K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 29,525 | 8,852 | $38K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.3% | 1,189 | 905 | $28K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 2,386 | 1,973 | $24K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.1% | 484 | 379 | $24K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 4,558 | 3,572 | $21K |
51 more codes
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 131 | $20K |
| 82607 | <1% | 1,554 | $14K | |
| 70220 | <1% | 713 | $13K | |
| 72100 | <1% | 529 | $8K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,861 | $8K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,108 | $7K |
| 84402 | <1% | 417 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,595 | $7K |
| 84403 | <1% | 417 | $6K | |
| 99406 | <1% | 1,050 | $6K | |
| 82962 | <1% | 4,184 | $6K | |
| 84439 | <1% | 905 | $5K | |
| 93000 | <1% | 384 | $3K | |
| 82670 | <1% | 190 | $3K | |
| 74018 | <1% | 238 | $3K | |
| 72040 | <1% | 145 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 194 | $2K |
| 99205 | Prolong outpt/office vis | <1% | 26 | $2K |
| 81002 | <1% | 932 | $1K | |
| 84153 | <1% | 184 | $1K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 18 | $1K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 26 | $872.27 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 49 | $588.00 |
| 86308 | <1% | 145 | $565.90 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,508 | $420.04 |
| 90756 | <1% | 35 | $389.06 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 16 | $388.45 |
| 90688 | <1% | 27 | $285.44 | |
| 90674 | <1% | 16 | $269.46 | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 1,362 | $260.28 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,773 | $238.59 |
| 90686 | <1% | 19 | $209.33 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 24 | $170.69 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 483 | $162.86 |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 19 | $156.28 |
| 86318 | <1% | 14 | $154.56 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 322 | $147.10 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 152 | $70.25 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 299 | $63.14 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 182 | $52.32 |
| J0945 | Injection, brompheniramine maleate, per 10 mg | <1% | 3,351 | $34.50 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 91 | $33.91 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 164 | $17.78 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 29 | $0.44 |
| J1071 | Injection, testosterone cypionate, 1 mg | 0% | 164 | $0.00 |
| J1000 | Injection, depo-estradiol cypionate, up to 5 mg | 0% | 165 | $0.00 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 125 | $0.00 |
| 90653 | 0% | 14 | $0.00 | |
| 3078F | 0% | 12 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 14 | $0.00 |
| 3074F | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORRIS, ASHLEY (MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Talkback, INC. | Johnson City, TN | $8.21M |
| Talkback ABA LLC | Johnson City, TN | $184K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.